Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer. (Selebrec)

National Cancer Institute, Naples

Status: Enrolling

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT05817227

57/21oss (Other Identifier)

SELEBREC

Details and patient eligibility

About

This is multicentric, spontaneous, observational, retrospective and prospective study.

Full description

In the retrospective part of the study, Tissue Microarrays (TMA) will be prepared from surgical samples of breast tissue from a series of patients with TNBC type breast cancer.

In the prospective part of the study will be evaluated the expression of some selenoproteins by ELISA in plasma samples obtained from up to 100 healthy subjects and about 300 (~100 per year) patients with basally metastatic TNBC breast cancer (150) and metastatic (150) before any treatment.

Enrollment: 300 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• TNBC breast cancer patients, before any drug treatment
• healthy women aged 25-60

Exclusion criteria

• donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.